ACADIA Pharmaceuticals Inc. (ACAD) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID rating (49/100 RQD Confidence). Alongside weak composite pillar scores, our SEC filing scanner spotted paper earnings outpacing operating cash flow (+103.4% (NI vs OCF)).
As of 2026-11-03, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $20.47 (-0.58% 1D, market cap $3.55B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 14/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACAD carries a Roarable D (49/100 RQD), trailing P/E of 9.1x, gross margin of 91.7%, and ROIC of 7.9%. By comparison, IRON (Disc Medicine Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -27.5%, cap $3.59B) and VKTX (Viking Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $3.48B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while ACAD leads on capital efficiency (7.9% ROIC).
Per ACAD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001070494), ACADIA Pharmaceuticals Inc. generated $1.07B in revenue (+11.9% YoY), $391.0M in net income, and $105.1M in free cash flow against $1.56B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 6.26 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC Form 4 / 13F Thermometer: 70% Net Buy • Cannibal Buyback (-1.80% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While ACAD currently carries a cautious 49/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Company leadership has skin in the game with net positive insider conviction.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.38) and Max Pain ($21.49) forces dealer call-delta covering toward $32.51.
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.80% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
ACADIA Pharmaceuticals Inc. (ACAD) slipped -0.58% to $20.47, trading at 17% of its 52-week range ($18.39 – $30.96). Weak 49/100 RQD score compounded by SEC accrual divergence (+103.4% (NI vs OCF)).
Yahoo Finance Singapore report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, October 28, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on Tuesday, November 17, 2026 at 12:40 p.m.
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +11.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ACAD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ACAD. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, ACADIA Pharmaceuticals Inc. (ACAD) ranks #271 by composite RQD confidence (49/100, grade D) and #192 by equity capitalization ($3.55B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while ACAD leads on capital efficiency and profitability with 7.9% ROIC and 91.7% gross margin. IRON currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with ACAD at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ACAD
ACTIVE
ACADIA Pharmaceuticals Inc. | D | 49/100 | 9.1x | 91.7% | 7.9% | -0.58% | $3.55B | Benchmark Subject |
| IRON Disc Medicine Inc. | D+ | 54/100 | — | — | -27.5% | -2.75% | $3.59B | /iron-vs-acad → |
| VKTX Viking Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -1.65% | $3.48B | /vktx-vs-acad → |
| AMLX Amylyx Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | -2.84% | $3.62B | /amlx-vs-acad → |
| XENE Xenon Pharmaceuticals Inc. | D- | 37/100 | — | — | -35.0% | +0.56% | $3.62B | /xene-vs-acad → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), ACADIA Pharmaceuticals Inc. (ACAD) reported GAAP revenue of $1.07B (+11.9% vs. FY2024 revenue of $957.8M , and +47.5% cumulative change since FY2023) , GAAP net income of $391.0M, operating cash flow of $109.8M, and free cash flow of $105.1M (-33.1% YoY). On the balance sheet, ACAD closed FY2025 with $1.56B in total assets against $0 in total debt (Altman Z-Score: 6.26, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.07B | $391.0M | $109.8M | $105.1M | $1.56B | — |
| FY2024 (FY) | 2024-12-31 | $957.8M | $226.0M | $157.7M | $157.2M | $1.19B | — |
| FY2023 (FY) | 2023-12-31 | $726.4M | -$61.0M | $16.7M | $16.7M | — | — |
As of 2026-11-03, ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $20.47 (-0.58% 1D, market cap $3.55B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 14/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACAD carries a Roarable D (49/100 RQD), trailing P/E of 9.1x, gross margin of 91.7%, and ROIC of 7.9%. By comparison, IRON (Disc Medicine Inc.) holds a D+ grade (54/100 RQD, P/E N/A, ROIC -27.5%, cap $3.59B) and VKTX (Viking Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $3.48B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while ACAD leads on capital efficiency (7.9% ROIC).
Per ACAD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001070494), ACADIA Pharmaceuticals Inc. generated $1.07B in revenue (+11.9% YoY), $391.0M in net income, and $105.1M in free cash flow against $1.56B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion. Institutional options positioning shows a 50% call / 50% put premium split.
ACAD last traded at $20.47 (-0.58% on volume of 1,384,994 shares), positioning the stock -12.45% below its 50-day simple moving average ($23.38) and -13.37% below its 200-day simple moving average ($23.63). Across its 52-week range of $18.39 to $30.96, ACAD sits at the 16.5% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±5.9% ($19.26 to $21.68).
ACADIA Pharmaceuticals Inc. (ACAD) earns a live Roarable RQD composite score of 49/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $20.47 (-0.58% 1D, market capitalization $3.55B).
ACADIA Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It operates with a market capitalization of $3.6B. Gross margin is reported at 91.7%, indicating a high gross-margin profile per the market data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), ACADIA Pharmaceuticals Inc. (ACAD) reported $1.07B in annual revenue (up from $957.8M in FY2024, +11.9% YoY) and $391.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($726.4M revenue, -$61.0M net income) through FY2025, ACAD scaled operating cash flow to $109.8M and free cash flow to $105.1M, backed by $1.56B in total assets against $0 in total debt.
Upstream and downstream dependencies, and sector correlations beyond the Health Care classification, are — The second-order item to watch is the accrual-quality signal: if the cash conversion gap identified in the forensic brief persists, the gap between reported earnings and operating cash flow would be the transmission channel through which earnings quality affects valuation. The 10-Q cash realization is the observable checkpoint named in the source.
Real-time company headlines, analyst actions, and sector developments for ACADIA Pharmaceuticals Inc. (ACAD) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Singapore report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering ACADIA Pharmaceuticals Inc. (ACAD) market action, institutional positioning, and fundamental catalysts.
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is why I am bullish on ACAD here at $20.59: Balance-sheet pillar scores 15/20 with Altman Z 6.26, Piotroski F 7/9, and Debt/Equity 0.5, and FY 2025 net income reached $391.0M.. Compare ACAD's 9.8% operating margin and 7.9% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $19.56 are getting bought.
Both sides have a point here — ACAD's 15/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Accrual signal (severity 82, BEARISH) flags net income growth of +73% outpacing operating cash flow growth of -30.4%, with a +103.4% cash conversion gap.. Look at the math on ACAD: paying 9.1x trailing P/E for 7.9% ROIC and 9.8% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $18.12 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).